Denali Therapeutics, Inc. (DNLI)
18.10
-0.30
(-1.63%)
USD |
NASDAQ |
May 19, 10:48
Denali Therapeutics Research and Development Expense (Quarterly) : 103.85M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen, Inc. | 471.10M |
| Neurocrine Biosciences, Inc. | 296.20M |
| Arcturus Therapeutics Holdings, Inc. | 20.92M |
| Agenus, Inc. | 11.82M |
| Curis, Inc. | 6.449M |